EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market, including revolutionary non-antibiotic antimicrobial products, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its novel intelli-Case with hydrogen peroxide solutions. Click here to view a presentation on intelli-Case. More than 24 million Americans n
Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual…
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, to…
Doheny Eye Institute has selected SriniVas Sadda, MD, as president and chief scientific officer, according to a press release.“When we embarked on the task of choosing a new president and CSO, our goal was to keep Doheny on the path of global leadership in basic and clinical vision research and advanced patient care,” Ed Landry, chairman of the Doheny board of directors, said in the release. “We are thrilled that Dr. Sadda has agreed to serve in this vitally important role for Doheny and are confident that he will continue (Read more...)
NovaBay Pharmaceuticals reported increases in product revenue and gross profit in the first quarter 2015 due to the commercialization of Avenova, according to a press release.Product revenue increased to $492,000 from $188,000 in the first quarter 2014…
Cataracts develop more frequently and at an earlier age in patients with diabetes, according to clinical and epidemiological studies. With the rapid increase of both type 1 and type 2 diabetes worldwide, the number of cataract surgeries in diabetic pat…